

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>OSPREY MEDICAL INC.</b>
<b>ABN</b>	<b>ARBN 152 854 923</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	John Erb
<b>Date of last notice</b>	19 May 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	30 June 2021

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held prior to change</b>	5,000	Options (OSPAO) with exercise price of US\$0.50 per Share
	73,839	Options (OSPAO) with exercise price of US\$0.25 per Share
	178,000	Options (OSPAO) with exercise price of A\$0.38 per Share
	80,000	Options (OSPAO) with exercise price of A\$0.26 per Share
	460,000	Options (OSPAO) with exercise price of A\$0.23 per Share
	626,568	Options with an exercise price of A\$0.05 per Share
	820,468	Options with an exercise price of A\$0.05 per Share
	1,500,000	Options with an exercise price of A\$0.034 per Share
	Total: <u>3,743,875</u> Options (OSPAO) (exercisable into an equivalent of 7,487,750 CDIs)	
<b>Class cancelled</b>	Options over Shares (not quoted)	
<b>No. of securities cancelled</b>	78,839	
<b>Number granted</b>	Nil	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil consideration.	

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	178,000	Options (OSPAO) with exercise price of A\$0.38 per Share
	80,000	Options (OSPAO) with exercise price of A\$0.26 per Share
	460,000	Options (OSPAO) with exercise price of A\$0.23 per Share
	626,568	Options with an exercise price of A\$0.05 per Share
	820,468	Options with an exercise price of A\$0.05 per Share
	1,500,000	Options with an exercise price of A\$0.034 per Share
	Total: <u>3,665,036</u> Options (OSPAO) (exercisable into an equivalent of 7,330,072 CDIs)	
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of 78,839 Options previously issued to Mr Erb.	

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.